Industry Pulse › RFK and the FDA July 2026 Peptide Decision May 24, 2026 · Regulatory Research Use Only. This article analyzes upcoming FDA regulatory activity in the context of research peptide supply chains. Genevium peptides are intended strictly for laboratory research purposes. Not approved for human consumption, clinical, therapeutic, veterinary, or diagnostic use. For …
More
RFK, the FDA, and Seven Peptides: What to Expect from the July 2026 PCAC Review
The FDA Peptide Reclassification of 2026: What Actually Changed, What’s Pending, and What It Means for Research Suppliers
Industry Pulse › The FDA Peptide Reclassification of 2026 May 23, 2026 · Regulatory In the first half of 2026, the FDA built and deployed a framework. The framework is clinical need, and it is now the lens through which every peptide compounding question will be evaluated going forward. Three regulatory actions between February and …
More
FDA Reverses Course on Seven Peptides: PCAC Reviews BPC-157, TB-500, KPV in July
The FDA Pharmacy Compounding Advisory Committee will convene July 23-24, 2026 to consider adding BPC-157, TB-500, KPV, Semax, Epitalon and others to the 503A bulks list. If recommended, compounding pharmacies could legally prepare these compounds for the first time.
More
FDA Moves to Ban Compounded Semaglutide and Tirzepatide: What Researchers Need to Know
Industry Pulse › FDA Moves to Ban Compounded Semaglutide and Tirzepatide May 1, 2026 · Regulatory On May 1, 2026, the FDA filed a proposal that would effectively end large-scale compounding of semaglutide, tirzepatide, and liraglutide in the United States. These are the active ingredients in Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, and Saxenda. If the …
More